CVC Capital Partners

CVC Capital Partners is one of the largest global alternative investment managers, with U.S. headquarters in New York and a long-standing track record across pharmaceuticals and medical devices. Within healthcare, its activity centers on Pharma/Therapeutics and Medical Devices/MedTech, typically through buyout or large minority structures rather than venture rounds. AI is not a dedicated thesis. CVC manages publicly significant assets globally; specific AUM is not provided in the input data.

Check sizes are $25M+, and in practice CVC writes far larger equity tranches when it leads a deal. The firm operates across Europe, Asia, and North America and gravitates toward profitable, mature companies with defensible market positions. Stage is growth/buyout, meaning relevance only kicks in at Series C+ scale or for established commercial-stage businesses. Specific portfolio companies are not listed in the source data.

For founders building physician AI tools, CVC is not a near-term fit. It becomes relevant only once a company has multi-year commercial revenue, regulatory clearance where applicable, and a credible path to a nine- or ten-figure outcome. The right profile is a CEO running a scaled MedTech or therapeutics platform exploring a recap, secondary, or growth round. Early-stage clinical AI founders should look elsewhere first.